Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
office: bldg. E35/186
Kamenice 753/5
625 00 Brno
phone: | +420 532 23 5494 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 78
2021
-
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
International Journal of Molecular Sciences, year: 2021, volume: 22, edition: 11, DOI
-
Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs.
Year: 2021, type: Conference abstract
-
Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia
Platelets, year: 2021, volume: 32, edition: 6, DOI
-
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro
Journal for ImmunoTherapy of Cancer, year: 2021, volume: 9, edition: 8, DOI
-
Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia.
Year: 2021, type:
-
In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation.
Year: 2021, type: Conference abstract
-
Kongenitální neutropenie u dětí a dospělých
Transfúze a hematologie dnes, year: 2021, volume: 27, edition: 4, DOI
-
Open Week
Year: 2021, type: Popularization text
2020
-
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
Plos one, year: 2020, volume: 15, edition: 3, DOI
-
Combination of epigenetic drug screen and CRISPR knockout screen as an unbiased approach to reveal possible CD20 therapy improvement
Year: 2020, type: Conference abstract